

To whom it may concern

April 23, 2024  
Nissan Chemical Corporation  
SANWA KAGAKU KENKYUSHO CO., LTD.

## **Nissan Chemical and Sanwa Kagaku Kenkyusho Announce Signing of Strategic Collaboration Agreement to Discover and Develop Oligonucleotide Therapeutics**

Nissan Chemical Corporation (Head office : Chuo-ku, Tokyo Japan, President: Shinsuke Yagi) and Sanwa Kagaku Kenkyusho Co., Ltd. (Head office : Nagoya city, Aichi Japan, President : Shusaku Isono) jointly announced today the signing of a strategic collaboration agreement to discover and develop oligonucleotide therapeutics for severe rare diseases with significant unmet medical needs.

Under the collaboration, Nissan Chemical and Sanwa Kagaku will collaborate on drug discovery research to identify potential novel oligonucleotide therapeutics. Nissan Chemical will design and synthesize oligonucleotide molecules against gene targets selected by both parties while Sanwa Kagaku will be responsible for efficacy and toxicity studies based on their remarkable track record in drug development.

The companies have already discovered a preclinical antisense candidate for a rare disease with no treatment options under their drug discovery collaboration agreement concluded in March 2019. Considering this achievement, Nissan Chemical and Sanwa Kagaku expand into the strategic collaboration to advance next-generation oligonucleotide therapeutics programs.

Nissan has established the oligonucleotide platform with its proprietary oligonucleotide technology such as a novel modified nucleic acid “MCE” and a single-stranded heteroduplex oligonucleotide “ss-HDO” to develop oligonucleotide therapeutics with high efficacy and safety.

### **About Nissan Chemical Corporation**

Nissan Chemical Corporation contributes to solving social issue providing products and services through four business areas – Performance materials, Agricultural chemicals, Chemicals, and Healthcare. We will acquire new technologies and accelerate growth in each business area by improving and combining core technologies.

Additional information is available at [www.nissanchem.co.jp/](http://www.nissanchem.co.jp/).

**About Sanwa Kagaku Kenkyusho Co., Ltd.**

Sanwa Kagaku Kenkyusho Co., Ltd. is a subsidiary of Suzuken Co., Ltd. who is one of the Japanese leading pharmaceutical wholesalers. We provide satisfactory drugs and diagnostic agents in the area of diabetes and kidney diseases. Our corporate philosophy is “Human-friendly 'medicines' for people in the world” and we offer services aimed at improving the quality of life of people wishing for good health.

Additional information is available at [www.skk-net.com](http://www.skk-net.com).

Contact information for inquiries on the above	
<p>Nissan Chemical Corporation Corporate Planning Department Planning Office, Public Relations Group E-mail : <a href="mailto:pr_cpd@nissanchem.co.jp">pr_cpd@nissanchem.co.jp</a></p>	<p>Sanwa Kagaku Kenkyusho Co., Ltd. Corporate Strategy Department CSR Public Relations Group E-mail : <a href="mailto:info-skk-2@ml.skk-net.com">info-skk-2@ml.skk-net.com</a></p>